Vident Investment Advisory, LLC Nektar Therapeutics Transaction History

Vident Investment Advisory, LLC

$0
Q3 2023

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.64 - $3.15 $542 - $2,671	848 Added 1.77%	48,709 $34,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $4.28 $337,915 - $712,453	-166,461 Reduced 77.67%	47,861 $108,000
Q3 2022 Nov 14, 2022	SELL	$3.04 - $5.14 $48,910 - $82,697	-16,089 Reduced 6.98%	214,322 $679,000
Q2 2022 Aug 15, 2022	BUY	$3.17 - $6.17 $424,016 - $825,293	133,759 Added 138.39%	230,411 $875,000
Q1 2022 May 16, 2022	BUY	$4.16 - $13.72 $52,000 - $171,500	12,500 Added 14.85%	96,652 $521,000
Q4 2021 Feb 14, 2022	SELL	$10.83 - $18.41 $6,768 - $11,506	-625 Reduced 0.74%	84,152 $1.14 Million
Q3 2021 Nov 12, 2021	SELL	$13.07 - $18.84 $201,617 - $290,625	-15,426 Reduced 15.39%	84,777 $1.52 Million
Q2 2021 Aug 13, 2021	SELL	$16.52 - $20.4 $8,309 - $10,261	-503 Reduced 0.5%	100,203 $1.72 Million
Q1 2021 May 14, 2021	BUY	$16.56 - $25.46 $10,465 - $16,090	632 Added 0.63%	100,706 $2.02 Million
Q4 2020 Feb 08, 2021	BUY	$15.77 - $19.03 $580,541 - $700,551	36,813 Added 58.19%	100,074 $1.7 Million
Q3 2020 Nov 12, 2020	SELL	$16.59 - $24.79 $148,961 - $222,589	-8,979 Reduced 12.43%	63,261 $1.05 Million
Q2 2020 Jul 17, 2020	BUY	$16.86 - $23.44 $27,279 - $37,925	1,618 Added 2.29%	72,240 $1.67 Million
Q1 2020 May 12, 2020	SELL	$14.47 - $27.96 $784,722 - $1.52 Million	-54,231 Reduced 43.44%	70,622 $1.26 Million
Q4 2019 Feb 11, 2020	BUY	$15.87 - $23.12 $1.32 Million - $1.93 Million	83,334 Added 200.71%	124,853 $2.7 Million
Q3 2019 Nov 13, 2019	SELL	$16.91 - $36.27 $258,029 - $553,443	-15,259 Reduced 26.87%	41,519 $756,000
Q2 2019 Aug 12, 2019	SELL	$31.0 - $36.3 $1.67 Million - $1.95 Million	-53,773 Reduced 48.64%	56,778 $2.02 Million
Q1 2019 May 08, 2019	BUY	$31.58 - $46.35 $1.73 Million - $2.54 Million	54,740 Added 98.08%	110,551 $3.71 Million
Q4 2018 Feb 14, 2019	SELL	$30.43 - $56.65 $12,689 - $23,623	-417 Reduced 0.74%	55,811 $1.83 Million
Q3 2018 Nov 14, 2018	BUY	$46.46 - $68.49 $150,251 - $221,496	3,234 Added 6.1%	56,228 $3.43 Million
Q2 2018 Aug 14, 2018	BUY	$46.25 - $104.45 $815,850 - $1.84 Million	17,640 Added 49.9%	52,994 $2.59 Million
Q1 2018 May 14, 2018	BUY	$57.4 - $108.44 $804,461 - $1.52 Million	14,015 Added 65.68%	35,354 $3.19 Million
Q4 2017 Feb 15, 2018	BUY	$23.02 - $60.5 $491,223 - $1.29 Million	21,339	21,339 $1.56 Million

Others Institutions Holding NKTR

# of Institutions

152

Shares Held

131M

Call Options Held

92.7K

Put Options Held

4.9K

Black Rock Inc. New York, NY

15.2M
Shares

$14.1 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

12.3M
Shares

$11.5 Million
0.0% of portfolio
Samlyn Capital, LLC New York, NY

9.67M
Shares

$8.99 Million
0.14% of portfolio
Nantahala Capital Management, LLC New Canaan, CT

7.81M
Shares

$7.26 Million
0.37% of portfolio
Acadian Asset Management LLC Boston, MA

7.2M
Shares

$6.7 Million
0.02% of portfolio

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $174M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Account